At a glance
ClinicalIndex Comparison RecordN/ACompleted· 63 enrolled
Drug / intervention
Lansoprazoledrug
Likely dose
Lansoprazole 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]
In Brief
An observational study evaluating Lansoprazole for Acute Stress Ulcer and Acute Gastric Mucosal Lesions. Completed, enrolled 63 participants.
Detailed Summary
The purpose of this survey is to evaluate the safety (that is, frequency of adverse events) and efficacy (that is, hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30 milligram (mg) (Takepron Intravenous 30 mg ) to a large number of participants with acute stress ulcer or acute gastric mucosal lesion in daily medical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
Primary CompletionMar 2010
First PostedJun 2014
TodayJul 2026
First PostedJun 23, 2014
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.0 years ago
Interventions
Lansoprazoledrug
Lansoprazole 30 mg injection